 |
|
Effect of omalizumab as add-on therapy to Quality of Life Questionnaire for Korean Asthmatics (KAQLQ) in Korean patients with severe persistent allergic asthma
Jae-Woo Jung, Hae-Sim Park, Choon-Sik Park, Sang-Heon Cho, Inseon S. Choi, Hee-Bom Moon, Soon Seog Kwon, Ho Joo Yoon, Jung Won Park, Jong-Myung Lee, Dong-Chull Choi, Byoung Whui Choi
Korean J Intern Med. 2021;36(4):1001-1013. Published online 2021 Jun 1 DOI: https://doi.org/10.3904/kjim.2020.549
|
|
Citations to this article as recorded by
 Roles of real-world evidence in severe asthma treatment: challenges and opportunities
Youngsoo Lee, Ji-Hyang Lee, So Young Park, Ji-Ho Lee, Joo-Hee Kim, Hyun Jung Kim, Sang-Heon Kim, Kian Fan Chung, Woo-Jung Song
ERJ Open Research.2023; 9(2): 00248-2022. CrossRef Omalizumab: An Optimal Choice for Patients with Severe Allergic Asthma
Serafeim Chrysovalantis Kotoulas, Ioanna Tsiouprou, Eva Fouka, Athanasia Pataka, Despoina Papakosta, Konstantinos Porpodis
Journal of Personalized Medicine.2022; 12(2): 165. CrossRef The Korean Severe Asthma Registry (KoSAR): real world research in severe asthma
Sang-Heon Kim, Hyun Lee, So-Young Park, So Young Park, Woo-Jung Song, Joo-Hee Kim, Heung-Woo Park, You Sook Cho, Ho Joo Yoon
The Korean Journal of Internal Medicine.2022; 37(2): 249. CrossRef
|